Post-marketing Study Assessing the Long-Term Safety of Abatacept

NCT02169544 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100000

Last updated 2017-04-25

No results posted yet for this study

Summary

The purpose of this study is to evaluate the risk of infections and malignancies among Rheumatoid Arthritis (RA) patients treated with Abatacept compared to other RA treatments.

Conditions

Interventions

DRUG

Abatacept

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2017-02-28
Completion
2017-02-28

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02169544 on ClinicalTrials.gov